ViiV Healthcare to present key data that provides further support for the use of 2-drug regimens, including long-term efficacy, alongside new insights into living with HIV at IDWeek 2021

Conference Reports for NATAP


ID Week Wed, Sep 29 - Sun, Oct 3, 2021 Virtual Conference

	Safety & Efficacy of SARS-CoV-2 Monoclonal Neutralizing Anibodies BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients - (12/03/21) Remdesivir For the Treatment of High-Risk Non-Hospitalized Individuals with COVID-19: A Randomized, Double, Blind, Placebo-Controlled Trial PINETREE Study -RDV for 3 day 87% reduction in hospitalization, there were no deaths in either arm - (12/03/21) Reasons for not using PrEP and actions that may facilitate PrEP uptake in Ontario and British Columbia, Canada - (10/17/21) Barriers to PrEP Implementation Among Patient-Facing Staff in Three Urban Clinics - (10/17/21) A Survey of HIV PrEP Prescribing Practices at an Academic Medical Center in the Pacific Northwest United States - (10/17/21) SUBOPTIMAL UPTAKE, RETENTION, AND ADHERENCE OF DAILY ORAL PREP AMONG PEOPLE WITH OUD RECEIVING HCV TREATMENT - (10/17/21) Bridging the Gap in PrEP Provider Training: An Implementation Science Study. insurance navigation for PrEP - (10/17/21) Preliminary Findings from a HIV Self-Testing Program among People Who Use Drugs - (10/06/21) Racial and Ethnic Disparities in COVID-19 Incidence among Persons with HIV in a Multisite-Cohort - (10/05/21) Lower SARS-CoV-2 IgG and Surrogate Virus Neutralization Titers Post-mRNA Vaccination among People Living with HIV - (10/05/21) Switch to DTG/3TC Noninferior to Maintaining TAF Regimen for 144 Weeks - Mark Mascolini (10/04/21) In Vitro Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence - (10/04/21) Increasing trends in multimorbidity and polypharmacy over a 5-year period in people living with HIV in the United States - Big US Study Confirms Ballooning Multimorbidity, Polypharmacy With HIV - (10/04/21) Accessible HCV Care for People who Inject Drugs: Randomized Clinical Trial Comparing Low-Threshold Treatment at a Syringe Service Program versus Facilitated Referral. - (10/04/21) Automated Hepatitis C Screening and Linkage to Care among Hospitalized Patients Born Between 1945-1965 - (10/04/21) EFFICACY AND SAFETY OF LONG-ACTING CABOTEGRAVIR + RILPIVIRINE IN PARTICIPANTS WITH HIV/HCV CO-INFECTION: ATLAS-2M 48-WEEK RESULTS - (10/04/21) Indirect Treatment Comparison of 48-Week Efficacy and Safety of Cabotegravir + Rilpivirine Long-Acting Every 2 Months to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Suppressed HIV-1-Infected Participants - (10/03/21) Implementation of Long-acting Injectable Cabotegravir-Rilpivirine for HIV-1 treatment at a Ryan White-funded Clinic in the U.S. South - (10/03/21) Renal function, Lipid profile, and Cardiovascular Events After Switching to Abacavir-containing Regimen in Antiretroviral-therapy-experienced People Living with HIV in Northern Thailand - (10/03/21) Use of tenofovir disoproxil fumarate shows weight loss vs placebo: a meta-analysis of 7 clinical trials in 19,359 HIV-negative individuals - (10/03/21) Interim Analysis of Real-World Community-Based HIV Rapid Start Antiretroviral with BFTAF Versus Conventional HIV Antiretroviral Therapy Start The RoCHaCHa Study a Pilot Study - (10/03/21) Long-term clinical outcomes following SARS-CoV-2 infection include persistent symptoms and cardiovascular disease beyond 3 months post-infection - (10/03/21) Monoclonal Regdanvimab Cuts COVID Progression Risk in Placebo Trial - Mark Mascolini (10/03/21) CHARACTERIZATION OF HEAVILY TREATMENT-EXPERIENCED HIV-1-INFECTED CLINICAL TRIAL PARTICIPANTS INFECTED WITH SARS-COV-2 COVID-19: FOSTEMSAVIR BRIGHTE PHASE 3 CLINICAL TRIAL - (10/03/21) Improvement in Diet Attenuates Antiretroviral Therapy (ART) Associated Weight Gain in Persons with Human Immunodeficiency Virus (PWH) Improved Diet Tied to Lower ART-Related Weight Gain in 870-Person US Study - Mark Mascolini (10/02/21) EFFECTIVENESS AND TOLERABILITY OF DTG+3TC IN CLINICAL PRACTICE: EVIDENCE IN PLHIV FROM REAL-WORLD DATA - (10/02/21) COVID-19 Symptoms Persist Beyond 1 Month in 25% of US Military Group - Mark Mascolini (10/02/21) Incidence of metabolic complications among treatment-naive adults living with HIV-1 randomized to B/F/TAF, DTG/ABC/3TC or DTG+F/TAF after 144 weeks. Low and Similar Rates of New Metabolic Problems: 3 Years With 3 ART Regimens - Mark Mascolini (10/02/21) Sex and race disparities in premature mortality among people with HIV: a 21-year observational cohort study - Premature Mortality Higher in Women and Blacks in US HIV Group - (10/01/21) Risk of Virologic Failure Among Treatment-experienced Suppressed People with HIV (PWH) Treated with Single-Tablet 2-Drug (2DR) vs 3-Drug (3DR) Regimens - Mark Mascolini (10/01/21) EFFECTS OF THE "UNDETECTABLE = UNTRANSMITTABLE" ("U=U") EDUCATIONAL CAMPAIGN ON TREATMENT OUTCOMES AND PERCEPTIONS AMONG PEOPLE LIVING WITH HIV IN NORTH AMERICAN COUNTRIES - (10/01/21) Strong HIV Control for 72 Weeks With B/F/TAF in US Blacks - Mark Mascolini (10/01/21) North American Phase 3/3b Experience With Long-Acting Cabotegravir and Rilpivirine: Efficacy, Safety, and Virologic Outcomes - (10/01/21) REAL-WORLD PERSISTENCY OF PATIENTS RECEIVING TENOFOVIR-BASED PRE-EXPOSURE PROPHYLAXIS FOR THE PREVENTION OF HIV INFECTION IN THE US - (10/01/21) Adherence to F/TDF for PrEP in Dried Blood Spots and HIV Infection Rates: A Pooled Analysis of Global PrEP Studies - (10/01/21) Pre-exposure prophylaxis (PrEP) prescriptions among individuals at high risk for HIV in the United States, 2012-2018 - (10/01/21) Persistence on F/TAF versus F/TDF for HIV Pre-Exposure Prophylaxis (PrEP): A Real-World Evidence Analysis in the United States - (10/01/21) Offering Drug Injectors PrEP While ID Inpatients Not Successful - Mark Mascolini (10/01/21) Lower CD4s and Higher Viral Load-Not Antiretrovirals-Tied to Excessive Weight Gain - Mark Mascolini (10/01/21) Treatment with molnupiravir in the MOVe-In and MOVe-Out clinical trials results in an increase in transition mutations across the SARS-CoV-2 genome - (09/30/21) Use of immune-viral dynamics modeling to understand molnupiravir drug effect for COVID-19 - (09/30/21) Clinical Characteristics of Patients Living with HIV Hospitalized for COVID-19 - PLWH have Higher Mortality Rate - (09/30/21) COVID Brings Drops in HIV Care Visits, Viral Load Measures, and ART Stops - Mark Mascolini (09/30/21) Remdesivir Linked to Viral Clearance Only in Certain Subsets - Mark Mascolini (09/30/21) Treatment with molnupiravir in the MOVe-In and MOVe-Out clinical trials results in an increase in transition mutations across the SARS-CoV-2 genome - (09/30/21) Use of immune-viral dynamics modeling to understand molnupiravir drug effect for COVID-19 - (09/30/21) Clinical Characteristics of Patients Living with HIV Hospitalized for COVID-19 - PLWH have Higher Mortality Rate - (09/30/21) Molnupiravir maintains antiviral activity against SARS-CoV-2 variants in vitro and in early clinical studies - (09/30/21) Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021 - (09/30/21) CHARACTERISTICS, COMORBIDITIES, AND MEDICATION BURDEN AMONG PEOPLE LIVING WITH HIV IN THE US MEDICARE PROGRAM - (09/30/21) Increasing trends in multimorbidity and polypharmacy over a 5-year period in people living with HIV in the United States - (09/30/21) The Efficacy and Safety of Maintenance With Doravirine Plus Two NRTIs After Initial Suppression in Adults With HIV-1 in the DRIVE-FORWARD Clinical Trial: Results From the Study Extension Through 192 Weeks - (09/30/21) High Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide in African-American Adults With HIV Including Those with Preexisting Resistance, Viral Blips, and Suboptimal Adherence - (09/30/21) QUALITATIVE PATIENT-PARTICIPANT PERSPECTIVES ON IMPLEMENTATION OF MONTHLY CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING (CAB+RPV LA) INJECTABLE IN THE UNITED STATES (CUSTOMIZE) - (09/30/21) Pregnancy Outcomes and Pharmacokinetics in Pregnant Women Living With HIV Exposed to Long-Acting Cabotegravir and Rilpivirine in Clinical Trials - (09/30/21) MATERNAL DOLUTEGRAVIR (DTG) USE, AND PREGNANCY AND BIRTH OUTCOMES: THE ANTIRETROVIRAL PREGNANCY REGISTRY (APR) - (09/29/21) HIGH RATES OF VIROLOGIC SUPPRESSION WITH DTG/3TC IN NEWLY DIAGNOSED ADULTS WITH HIV-1 INFECTION AND BASELINE VIRAL LOAD ≥500,000 C/ML: 48-WEEK SUBGROUP ANALYSIS OF THE STAT STUDY - (09/29/21) Interim Resistance Analysis of Long-Acting Lenacapavir in Treatment-Naïve People with HIV at 28 Weeks (CALIBRATE) - (09/29/21) SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN IN MAINTAINING VIROLOGIC SUPPRESSION THROUGH 144 WEEKS (TANGO STUDY) - (09/29/21) Long-term Outcomes of Participants on F/TAF for Pre-Exposure Prophylaxis: Results for 144 Weeks of Follow-Up in the DISCOVER Trial - (09/29/21) Incidence of metabolic complications among treatment-naive adults living with HIV-1 randomized to B/F/TAF, DTG/ABC/3TC or DTG+F/TAF after 144 weeks. Low and Similar Rates of New Metabolic Problems: 3 Years With 3 ART Regimens - Mark Mascolini (09/29/21) Monoclonal Lenzilumab Cuts Need for Ventilation in Phase 3 COVID Trial - Mark Mascolini (09/29/21) Invasive Pneumococcal Disease Rate 17-Fold Higher With HIV in US - Mark Mascolini - (09/29/21) ViiV Healthcare to present key data that provides further support for the use of 2-drug regimens, including long-term efficacy, alongside new insights into living with HIV at IDWeek 2021 - (09/29/21)